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Immune cells are critically involved in placental development and functioning, and
inadequate regulation of the maternal immune system is associated with placental
pathology and pregnancy complications. This study aimed to explore numbers of
decidual immune cells in pregnancies complicated with fetal growth restriction (FGR)
and stillbirth (SB), and in placentas with histopathological lesions: maternal vascular
malperfusion (MVM), fetal vascular malperfusion (FVM), delayed villous maturation (DVM),
chorioamnionitis (CA), and villitis of unknown etiology (VUE). Placental tissue from FGR (n
= 250), SB (n = 64), and healthy pregnancies (n = 42) was included. Histopathological
lesions were classified according to criteria developed by the Amsterdam Placental
Workshop Group. Tissue slides were stained for CD68 (macrophages), CD206 (M2-like
macrophages), CD3 (T cells), FOXP3 [regulatory T (Treg) cells], and CD56 [natural killer
(NK) cells]. Cell numbers were analyzed in the decidua basalis using computerized
morphometry. The Mann-Whitney U-test and Kruskal Wallis test with the Dunn’s as
post-hoc test were used for statistical analysis. Numbers of CD68+ macrophages were
higher in FGR compared to healthy pregnancies (p < 0.001), accompanied by lower
CD206+/CD68+ ratios (p < 0.01). In addition, in FGR higher numbers of FOXP3+ Treg
cells were seen (p < 0.01) with elevated FOXP3+/CD3+ ratios (p < 0.01). Similarly, in SB
elevated FOXP3+ Treg cells were found (p < 0.05) with a higher FOXP3+/CD3+ ratio
(p < 0.01). Furthermore, a trend toward higher numbers of CD68+ macrophages was
found (p< 0.1) in SB. Numbers of CD3+ and FOXP3+ cells were higher in placentas with
VUE compared to placentas without lesions (p < 0.01 and p < 0.001), accompanied
by higher FOXP3+/CD3+ ratios (p < 0.01). Elevated numbers of macrophages with a
lower M2/total macrophage ratio in FGR suggest a role for a macrophage surplus in its
pathogenesis and could specifically indicate involvement of inflammatory macrophages.
Higher numbers of FOXP3+ Treg cells with higher Treg/total T cell ratios in VUE may
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be associated with impaired maternal-fetal tolerance and a compensatory response of
Treg cells. The abundant presence of placental lesions in the FGR and SB cohorts might
explain the increase of Treg/total T cell ratios in these groups. More functionality studies
of the observed altered immune cell subsets are needed.
Keywords: pregnancy, macrophage, regulatory T cell, natural killer cell, placental pathology, fetal growth
restriction, stillbirth
INTRODUCTION
Five to ten percent of pregnancies is complicated by fetal
growth restriction (FGR) (1). FGR is defined as a fetus that
is unable to reach its intrinsic growth potential (2). It is
associated with an increased risk of neonatal mortality and
morbidity (3, 4) and adverse long term effects, like impaired
neurodevelopment and cardiovascular, endocrine, and metabolic
diseases (5). Abnormal placentation leading to placental
insufficiency is the most common underlying pathophysiology
in FGR (6–8). Additionally, placental senescence is seen with
upregulation of pro-inflammatory cytokines, contributing to
placental inflammation and oxidative stress (8). FGR is thought
to be responsible for nearly one third of stillborn (SB)
infants (1, 5), however, a large part of intrauterine deaths
remains unexplained (9). Numbers of SB are large, with an
estimated 2.6 million cases in 2015 worldwide (10). Placental
pathology is a common finding in SB and FGR (11, 12).
The main placental lesions found in pregnancy complications
are classified as maternal vascular malperfusion (MVM),
fetal vascular malperfusion (FVM), delayed villous maturation
(DVM), chorioamnionitis (CA), and villitis of unknown etiology
(VUE) (13).
The role of the maternal immune system in pregnancy
complications has gained increasing attention, with specific
interest for the involvement of immune cell subsets in placental
development and functioning, and maternal-fetal tolerance. The
maternal immune system is subjected to paternal antigens
expressed by the fetus via direct contact between fetal trophoblast
cells, present in the villous tissue and spiral arteries, and maternal
blood (14). Moreover, transfer of fetal and/or placental cells and
DNA through the placental barrier into the maternal circulation
occurs throughout gestation, referred to as micro-chimerism
(15–18). This requires a state in which maternal immune cell
subsets cooperate to ensure a tolerogenic environment for the
developing fetus (19).
In healthy pregnancies, immune cells are balanced toward
an immunoregulatory phenotype. For example, macrophages
predominantly express an anti-inflammatory,M2-like phenotype
that is involved in tissue remodeling and homeostasis (20–24),
numbers of Treg cells participate in preserving maternal-fetal
tolerance (25–31), and numbers increase in response to fetal
alloantigen (32), and NK cells show a reduction of the cytotoxic
subset and an increase in NK cells with immunomodulatory
potential (33–36). Furthermore, macrophages and NK cells have
been attributed important roles in various aspects of placental
development, including trophoblast invasion, spiral artery (SA)
remodeling, and tissue regeneration and angiogenesis (37–
43). Moreover, exaggerated maternal immune responses can be
seen in combination with inflammatory histologically placental
lesions that are commonly found in pregnancy complications
(44, 45). Inadequate adaptation of the maternal immune system,
in particular at the maternal fetal interface, has been widely
described in adverse pregnancy outcomes like preeclampsia (29,
46–49), preterm birth (50–52), and spontaneous pregnancy loss
(28, 53, 54). However, little is known about possible immune
cell imbalances in FGR and SB. As placental malfunctioning is
thought to be a key factor in the cause or exacerbation of these
complications of pregnancy (6–8, 11, 12), it is likely that altered
immune cell balances are at play.
Obtaining more insight into the presence of decidual
macrophages, T cells, Treg cells, and NK cells in healthy
and complicated pregnancies provides a basis for better
understanding the role of these immune cells in the pathogenesis
of pregnancy complications. The present study therefore aims
to explore the number of decidual macrophages, the M2
macrophage subset, T cells, Treg cells, and NK cells in FGR and
SB, and associated types of placental lesions, MVM, FVM, DVM,
CA, and VUE, in order to generate hypotheses on immune cell
subsets involved in these pregnancy complications.
MATERIALS AND METHODS
Study Design
Study cases with placenta samples and histology reports of
three historical study cohorts were included. The DIGITAT
cohort (Disproportionate Intrauterine Growth Intervention At
Term) included women between 36 and 41 weeks of pregnancy
with a singleton with suspected FGR diagnosed by a small for
gestational age (SGA) fetus: a fetal abdominal circumference
below the 10th centile, estimated fetal weight below the 10th
centile or a decreased relative growth in the third trimester
(as judged by a clinician) though still above the 10th centile.
Exclusion criteria were a history of cesarean section (CS),
serious congenital defects, ruptured membranes, renal diseases,
diabetes mellitus, or a positive HIV serology (55). The ZOBAS
cohort (“Zinnig Onderzoek Bij Antepartum Sterfte,” transl.
Useful Examination in Antepartum Death) included all singleton
intrauterine fetal deaths diagnosed antepartum after 20 weeks
of gestation. SB was diagnosed if fetal heartbeat ceased before
labor. We included all women who gave birth from 36
weeks of gestation onwards. Exclusion criteria were pregnancy
terminations (for congenital malformations) and intrapartum
deaths (56). The NORMA cohort comes from a local study
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performed at the University Medical Center Groningen that
included healthy pregnancies. Fetuses with a birth weight above
the 10th centile and below the 90th centile were selected as
our control cohort. Women who gave birth from 36 weeks
onward were included, provided that their blood pressure was
within the normal range, their pregnancies were not complicated
by preeclampsia, and women did not use medication. In total,
samples of 250 FGR, 64 SB, and 42 healthy pregnancy cases could
be included. The hematoxylin eosin (HE) stained tissue slides
were re-analyzed and classified for placental histologic lesions by
a single perinatal pathologist blinded for clinical details according
to the latest international criteria developed by the Amsterdam
Placental Workshop Group (13).
Immunohistochemistry
After delivery, the placentas were fixed in formalin; one full-
thickness sample of normal-appearing parenchyma from within
the central two-thirds of the placental disc for each case was
taken, and embedded in paraffin. Biopsies were taken according
to the hospital sampling protocol as later described by the
Amsterdam Placental Workshop Group (13). Tissue sections of
3µm thickness were cut in consecutive slides where possible.
Primary antibodies used were CD68 (PGM1, Agilent Dako,
USA), CD206 (5C11, BioRad, USA), CD3 (2GV6, Ventana,
USA), FOXP3 (236A/E7, Abcam, USA), and CD56 (MRQ-42,
Ventana, USA). IHC was performed manually for CD206 and
FOXP3. Slides were deparaffinized with xylene and washed in
PBS. Antigen retrieval was performed with 10mM Tris/1mM
EDTA pH 9.0 solution in the microwave for 15min at 300 or
500 Watt, cooled down for 20min at room temperature and
washed with PBS for 5min. Blocking endogenous peroxidase was
done using 500 µl 30% H2O2 in 50ml PBS for 30min. Slides
were washed in PBS for 5min and incubated for 60min with
the primary antibody FOXP3 in a dilution of 1:100, or with
the primary antibody CD206 in a dilution of 1:800. Slides were
then again washed in PBS for 5min, followed by incubation with
the peroxidase-labeled rabbit-anti-mouse (RAMpo) secondary
antibody (Agilent Dako, USA) with 1% NHS in a dilution
of 1:100 for 30min and the tertiary peroxidase-labeled goat-
anti-rabbit (GARpo) antibody (Agilent Dako, USA) with 1%
NHS diluted 1:100 for 30min with an additional washing
step after each antibody incubation. Slides were incubated
for 10min in ultra 3,3′-diaminobenzidine-tetrahydrochloride
(DAB) peroxidase, diluted in 50ml PBS and 50 µl 30% H2O2.
After washing in demi water, hematoxylin counterstaining was
performed. Slides were dehydrated, dried and covered with
mounting medium and a cover slip. For CD68, CD3, and CD56,
IHC was performed with the Ventana Benchmark Ultra machine
with the Ultraview DAB Kit (Ventana, USA). Deparaffinizing the
slides and blocking of endogenous peroxidase is an automatized
process performed in the machine at 72◦. Antigen retrieval was
performed with a 10mM Tris/1mM EDTA pH 9.0 solution
52min for CD68 and 36min for CD3 and CD56. Slides were
incubated with the primary antibodies, 28min for CD68 and
32min for CD3 and CD56. CD68 was diluted to 1:100, CD3
and CD56 antibodies were delivered ready to use. For CD56,
an Amplification Kit (Ventana, USA) was used to increase the
signal intensity of the CD56 primary antibody. The Tissue-Tek
Prisma E2S machine was used to automatically perform the DAB
reaction, hematoxylin counterstaining, and dehydration of the
slides and application of a cover slip.
Slides were scanned with the Philips Intellisite Pathology
Solution Ultra-Fast scanner 1.6.1.1.12. In the scans for FOXP3,
the number of cells was manually counted due to the low number
of cells in each tissue slide. Digital analysis was performed
using Visiopharm version 2018.4. In order to create automatic
detection classifiers to count the number of cells, scans for CD68,
CD206, CD3, and CD56 were analyzed with QuPath version 0.1.2
(57). In short, distinct cell types (e.g., stromal cells, immune cells,
background staining) were manually labeled in decidual tissue
based on staining pattern and cell morphology.With this labeling
set as example, an automatic detection classifier was built and
applied on all tissue slides to count the immune cells of interest.
Separate classifiers were developed for each immune cell subset.
Detailed instructions can be found online (58).
An example of the detection classifier developed to analyze
CD68+ macrophages can be found in Supplementary Figure 1.
In both programs, all decidua basalis tissue in the tissue
section was encircled as region of interest. Availability of
viable decidual tissue, therefore size of the encircled area,
varied per section. Placental septa, decidua tissue overlying
large villous infarcts, areas consisting of fibrin without visible
trophoblast cells and decidualized endometrium stromal
cells and areas with hemorrhage were not included in the
encircled surface area. The encircling of the decidua and the
development of the detection classifier was performed by
two of the authors. As shown in Supplementary Figure 1,
the detection classifier distinguished three levels of color
intensity for each IHC stain. All positive stained cells
were analyzed as immune cells, regardless of the detected
intensity of staining. The decidual surface was given in
µm2 and the outcome calculated as number of cells/mm2
decidual tissue.
Statistical Analysis
IBM SPSS Statistics 23 was used for statistical analyses.
QQ-plots and the Shapiro-Wilk test were used to test the
normality of the distribution. The Chi-square test was used for
categorical data, the independent sample T-test for normally
distributed continuous data and the Mann-Whitney U-test
for not normally distributed continuous data. To compare
between multiple groups, the Chi-square test was used for
categorical data with pairwise Chi-square with Bonferroni
correction as a post-hoc test. The one-way ANOVA was
used for normally distributed data with Tukey’s HSD as
a post-hoc test. The Kruskal Wallis test was used for not
normally distributed data with the Dunn’s non-parametric
comparison as a post-hoc test. Similarity of distributions across
the patient groups was confirmed by visual inspection of
boxplots. Finally, to determine whether the associations between
immune cell subsets and patient groups (FGR, SB, healthy
controls, and placental lesion groups) were independent of
smoking status, we performed linear regression analyses. A p
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TABLE 1 | Patient characteristics of the FGR, SB, and control cohort.
Control (n = 42) FGR (n = 250) SB (n = 64)
Maternal age (years) 31.51 ± 4.83 29.39 ± 5.50 31.66 ± 4.84
Maternal BMI (kg/m2 ) – 23.66 ± 5.30 27.12 ± 5.50
Smoking during pregnancy 10 (23.8%) 100 (40%)* 18 (28.1%)
Parity
Nulli (0) 19 (45.2%) 152 (60.8%) 29 (43.8%)
Primi (1) 15 (35.7%) 60 (24%) 13 (20.3%)
Multi (2–4) 5 (19.0%) 35 (14%) 19 (28.1%)
Grande multi (>4) 0 (0%) 3 (1.2%) 3 (4.7%)
GA at birth (days) 278.45 ± 11.98 270.45 ± 9.83*** 275.33 ± 11.32***
Sex
Boy 23 (54.8%) 101 (40.4%) 32 (50%)
Girl 19 (45.2%) 147 (58.8%) 30 (46.9%)
Neonatal weight (grams) 3464.88 ±457.48 2296.42 ± 340.52*** 3169.52 ± 639.821***
Neonatal weight centile
<p3 0 (0%) 203 (81.2%)*** 12 (18.8%)***
p3–p5 0 (0%) 16 (6.4%) 6 (9.4%)
p5–p10 0 (0%) 15 (6.0%) 4 (6.3%)
>p10 42 (100%) 14 (5.6%) 40 (62.6%)
Placental weight (grams) 537.00 ± 97.14 360.71 ± 86,46*** 436.18 ± 113.49***
Patient characteristics are shown for the FGR (n = 250), SB (n = 64), and control (n = 42) cohorts. Continuous data is presented as mean + SD and compared between groups using
the one-way ANOVA with Tukey HSD as a post-hoc test. Categorical data is presented as number + percentage and compared using the Chi-square test with Bonferroni correction as
a post-hoc test. Significance presented as p-value compared to the control group. *Significant at p < 0.05. ***Significant at p < 0.001. FGR, fetal growth restriction; SB, stillbirth; GA,
gestational age.
< 0.05 was considered significant, a p < 0.1 was considered a
statistical trend.
Ethics
Approval of the Medical Ethical Evaluation Committee (METc)
has been obtained for the DIGITAT (Leiden University
medical Center, Leiden, the Netherlands: P04.210), and
ZOBAS (University Medical Center Groningen, Groningen,
the Netherlands: M02.00671). The present study has been
conducted in accordance with the METc recommendations. For
the NORMA study placental tissue was used according to the
code of conduct for responsible use following the guideline from
the Federation of Medical Scientific Associations with approval
of the METc.
RESULTS
Patient characteristics are presented in Table 1. No significant
differences were found for maternal age, fetal sex, and parity
between FGR and SB and healthy pregnancies. Gestational age
(GA) at birth, birth weight, and placental weight were lower in
the FGR group (p< 0.001, p< 0.001, and p< 0.001, respectively)
and SB group (p < 0.001, p < 0.001, and p < 0.001, respectively)
compared to the control group. More neonates from the FGR
and SB groups had a birth weight <p3 compared to the control
group (p < 0.001 and p < 0.001, respectively). The percentage
of women who smoke during pregnancy was higher in the FGR
group compared to control group (p < 0.05).
Immune Cell Subsets in Adverse
Pregnancy Outcomes
For each immune cell, we determined the number of cells
per mm2 decidual tissue and compared this between FGR
and healthy pregnancies, and SB and healthy pregnancies.
In addition, we determined the CD206+/CD68+ and
FOXP3+/CD3+ ratios.
Immune Cell Subsets in the FGR Cohort: Higher
Numbers of Macrophages With Lower M2/Total
Macrophage Ratios, and Higher FOXP3+/CD3+
Ratios
The number of CD68+ macrophages was significantly higher
in decidual tissue of FGR pregnancies compared to control
pregnancies (p < 0.001) and showed an increase of more than
50% in the FGR group. Although absolute numbers of CD206+
cells (M2-like macrophages) were comparable between the
FGR pregnancies and control pregnancies, the CD206+/CD68+
ratio was significantly lower in the FGR cohort compared
to controls (p < 0.01). In addition, numbers of FOXP3+
Treg cells were increased in FGR (p < 0.01) accompanied by
a higher FOXP3+/CD3+ T cell ratio (p < 0.01; Figures 1,
2A,B). Linear regression analysis and comparing the cohorts
with exclusion of all women who smoke in the FGR and
control cohort, showed that these findings were independent
of smoking status. Numbers of CD3+ T cells, and CD56+ NK
cells were comparable between FGR and healthy pregnancies
(Figure 2A).
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FIGURE 1 | IHC results of macrophages in FGR and controls. Presence of CD68+ macrophages and CD206+ M2 macrophages in FGR (n = 250) and controls (n =
42). 20x magnification. Arrows set as example of CD68+ and CD206+ cells, not all positive cells are indicated. FGR, fetal growth restriction.
Immune Cell Subsets in the SB Cohort: Higher
FOXP3+/CD3+ Ratios
Significantly higher numbers of FOXP3+ T cells were found in
SB compared to healthy pregnancies (p < 0.05), as well as a
higher FOXP3+ Treg/CD3+ ratio in SB compared to control (p
< 0.01). These findings were independent of smoking status in
the linear regression analysis, however, a significant difference
was not found after excluding all women that smoke from the
cohorts (Figures 3, 4A,B). Moreover, a trend was found for
higher numbers of CD68+ macrophages in SB compared to
healthy pregnancies (p < 0.1), however, the higher numbers
of CD68+ macrophages did not remain to be a trend after
correcting for smoking status. Numbers of CD56+ NK cells
and CD206+ M2-like macrophages were comparable in the SB
and healthy pregnancies (Figure 4A). Likewise, no differences in
CD206+ M2-like/CD68+ total macrophage ratio were found in
SB compared to healthy pregnancies (Figure 4B).
Immune Cell Subsets in Placental Lesions
In addition to adverse pregnancy outcomes, we studied the
numbers of immune cells in histopathologic placenta lesions.
Distribution of Placental Lesions in FGR, SB, and
Healthy Pregnancies
First, the prevalence of lesions was determined in each
cohort (Figure 5). Placental lesions were grouped into placentas
diagnosed with a single lesion (MVM, FVM, DVM, CA, or
VUE), a combination of multiple lesions (ML) and no lesions
(NL). Cases with DVM were only observed in the SB cohort.
The incidence of multiple lesions was highest in pregnancies
complicated with SB compared to FGR (p< 0.01) and the control
group (p < 0.05). In the FGR cohort, the multiple lesion group
was predominated by VUE which was present in 45 out of 70
multiple lesions cases (64%). In the SB cohort, the multiple
lesion group was predominated by CA present in 19 out of 24
multiple lesion cases (79%). The control cohort had only 4 cases
of multiple lesions, predominated by VUE in 3 out of 4 cases
(75%). Placentas without lesions were more frequently found in
the FGR and control cohort, compared to the SB cohort (p <
0.01) and (p < 0.01). VUE occurred more in the FGR compared
to SB cohort (p < 0.05), whereas placentas showing signs of CA
were mostly found in the control cohort and showed a significant
difference compared to the FGR cohort (p < 0.001).
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FIGURE 2 | Comparison of immune cell subsets and ratios between FGR and controls. (A) Number of cells/mm2 are shown for CD68+ macrophages, CD206+ M2
macrophages, CD3+ T cells, FOXP3+ Treg cells, and CD56+ NK cells and compared between the FGR (n = 250) and controls (n = 42) cohorts with the
Mann-Whitney U-test. Data presented as median + IQR. **p < 0.01, ***p < 0.001. (B) Ratios of number of cells/mm2 are shown for CD206+/CD68+ macrophages
and FOXP3+/CD3+ T cells and compared between FGR (n = 250) and controls (n = 42) with the Mann-Whitney U-test. Data presented as median + IQR. **p < 0.01.
FGR, fetal growth restriction.
Immune Cell Subsets in Placental Lesions in the FGR
Cohort: Higher Numbers of T and Treg Cells and
Higher Treg/T Cell Ratios in VUE
Due to the low number of cases in each lesion group within
the SB and control cohort, we decided to compare the immune
cell numbers between placental lesion groups in the FGR cohort
only. The number of decidual CD3+ T cells was significantly
higher in VUE and multiple lesions compared to no placental
lesions (p < 0.01 and p < 0.001, respectively). These higher
numbers of CD3+ T cells were accompanied by significantly
higher numbers of decidual FOXP3+ Treg cells in placentas
showing signs of VUE (p < 0.001) and multiple lesions (p
< 0.001) compared to placentas without lesions (Figures 6,
7A). To determine if the observed higher numbers of FOXP3+
Treg cells were related to the number of CD3+ T cells in the
decidua, we determined the FOXP3+/CD3+ ratio. Our results
show a significantly higher FOXP3+ Treg cell/CD3+ total T
cell ratio in VUE and the multiple lesion group compared to
no lesions (p < 0.01 and p < 0.05, respectively), which was
independent of smoking behavior. This could indicate not only
an absolute but also a relative increase in FOXP3+ Treg cells
(Figure 7B). Higher numbers of CD206+ M2-like macrophages
were observed in placentas with multiple lesions compared
to placentas with no lesions (p < 0.05), although this did
not result in differences in the CD206+ M2-like/CD68+ total
macrophage ratio (Figures 7A,B). We did not find differences in
numbers of CD56+ NK cells and CD68+ macrophages among
the lesion groups.
Since FOXP3+/CD3+ ratios were increased in both FGR,
SB, and the VUE and ML groups, we performed a sub analysis
in order to determine whether the presence of VUE and
multiple lesions could be responsible for the relative increase
of FOXP3+ Treg cells in FGR and SB. We excluded all cases
of VUE and multiple lesions from the FGR, SB and control
cohorts and the differences in FOXP3+/CD3+ ratios did not
remain significant.
DISCUSSION
The main finding of this study is that in FGR, decidual
macrophages appear to have a more inflammatory phenotype
compared to healthy pregnancies. Our findings are in accordance
with previous studies that found preeclampsia, spontaneous
pregnancy loss, and preterm birth to be associated with higher
numbers of total macrophages with increased expression of
an M1-like, pro-inflammatory macrophage phenotype (47, 50,
53, 54, 59–61). Moreover, a recent study found an increase of
placental macrophages in pregnancies in which the fetus showed
a decreased growth rate in the third trimester, accompanied by
elevated pro-inflammatory markers in the placenta and maternal
blood (62). The authors propose placental senescence as a
mechanism for placental dysfunction in FGR, underpinned by
the absence of elevated CD45+ leukocytes and clinical signs of
infection, as well as upregulation of DAMPs, associated with
oxidative stress, necrosis, and cellular injury. Similar results were
seen in a uric-acid induced placental inflammationmouse model,
were pups developed FGR and an increase of macrophages was
found in the placental junctional zone (63). Contrary to our
results, another study has reported lower numbers of CD14+
macrophages in the placental bed in FGR compared to healthy
pregnancies, although this did not reach a significant level
(49). These differences could be due to the use of different
markers and/or a different placenta sampling location. To our
knowledge, our study is the first to find increases of macrophages
in the decidual tissue, accompanied by altered subset balances.
Since placental insufficiency in FGR can arise at multiple
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FIGURE 3 | IHC results of T cells and Treg cells in SB and controls. Presence of CD3+ T cells and FOXP3+ Treg cells in SB (n = 64) and controls (n = 42). 20x
magnification. Arrows indicate all FOXP3+ cells. Arrows set as example for CD3+ T cells, not all positive cells are indicated. SB, stillbirth.
FIGURE 4 | Comparison of immune cell subsets and ratios between SB and controls. (A) Number of cells/mm2 are shown for CD68+ macrophages, CD206+ M2
macrophages, CD3+ T cells, FOXP3+ Treg cells and CD56+ NK cells and compared between the SB (n = 64) and controls (n = 42) cohorts with the Mann-Whitney
U-test. Data presented as median + IQR. #p < 0.1, *p < 0.05. (B) Ratios of number of cells/mm2 are shown for CD206+/CD68+ macrophages and FOXP3+/CD3+
T cells and compared between SB (n = 64) and controls (n = 42) with the Mann-Whitney U-test. Data presented as median + IQR. **p < 0.01. SB, stillbirth.
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FIGURE 5 | Distribution of placental lesions across the FGR, SB and control cohorts. Percentages of specific lesions, and comparison between the FGR (n = 250),
SB (n = 64), and control (n = 42) cohort with the Chi-square test. No cases of DVM as a single lesion were present in the FGR and control cohorts. No cases of MVM
as a single lesion were present in the control cohort. *p < 0.05, **p < 0.01, ***p < 0.001 (p-values adjusted using Bonferroni correction).
levels, ranging from early placental developmental defects in
trophoblast invasion and SA remodeling, to placental senescence
with inflammatory and hypoxic events throughout the course
of gestation (8), the question remains from which point in
pregnancy the altered macrophage balances originate and how
they contribute to the pathogenesis or exacerbation of FGR.
Furthermore, the finding that the altered macrophage balances
in the decidua appears maternal in origin is an interesting
finding in terms of preserving maternal-fetal tolerance and it
could be hypothesized that an exaggerated maternal immune
response to the fetal and placental tissue is involved. Our results
indicate that altered decidual macrophage balances could be
involved in FGR and mark the importance of more research
on this topic. We suggest performing functionality studies on
decidual macrophages and a broader characterization of their
phenotype at different time points in gestation to determine their
contribution to FGR.
Overall, the incidence of placental lesions was higher in
FGR and SB compared to the control group. Interestingly,
chorioamnionitis (CA) formed an exception and was found to be
more frequently present in placentas from healthy pregnancies,
a finding that can most likely be attributed to differences
in onset of labor. In the majority of the controls, delivery
occurred spontaneously in healthy pregnancies, whereas in the
pregnancies complicated by FGR and SB a majority of women
had induction of labor. It has earlier been shown that CA
is seen more often in pregnancies with spontaneous onset of
labor, compared to induction (64) and compared to cesarean
section (65). This finding has been explained by the physiological
inflammatory process that precedes spontaneous parturition,
associated with the presence of inflammatory markers in the
myometrium, cervix and chorioamniotic membranes (64). Also
in a sub analysis of the DIGITAT trial, CA was more frequently
present FGR pregnancies with spontaneous labor compared to
induction (66).
When examining the presence of immune cell subsets in
common placental lesions within the FGR cohort we showed
higher numbers of FOXP3+ Treg cells and CD3+ T cells, as
well as a relative increase in FOXP3+ Treg cells in cases of VUE
and multiple lesions. VUE is characterized by an inflammatory
infiltrate of Hoffbauer cells and maternal CD4+ and CD8+
T cells (67, 68) with irregular involvement of the chorionic
villi and areas of placental parenchyma that remain unaffected
(69). The etiology of VUE remains poorly understood. Since
not an infective organism can be identified, its cause has been
explained by either a non-diagnosed underlying infection or an
exaggerated maternal immune response to the paternal antigens
expressed on the fetal villous tissue (67–70). Interestingly,
placentas with VUE show upregulation of MHC class I and II
on fetal trophoblast, accompanied by an increase of chemokines
within the placenta and maternal and fetal circulation, indicating
a systemic inflammatory response in both mother and fetus. This
finding supports the hypothesis of a graft vs. host-like response
in VUE (71). VUE has been abundantly associated with FGR
(69, 70, 72–75). The reported incidence of histological findings
of VUE in FGR widely varies, which might be explained by
differences in diagnostic criteria. In our study, in which we used
the latest international criteria for classifying placental pathology
(13), we found VUE to be present in 18% of FGR cases compared
to 7% in healthy controls. The increase of Treg cells in VUE
at the inflammatory sites in the villous parenchyma, was first
shown by Katzman et al. They propose that Tregs infiltrate
these sites in order to regulate the immune responses that are
potentially harmful toward the fetus (76). As we studied the
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FIGURE 6 | IHC results of Treg cells and T cells in VUE and no lesions in the FGR cohort. Presence of CD3+ T cells and FOXP3+ Treg cells in VUE (n = 45) and no
lesion (n = 44) within the FGR cohort. 20x magnification. Arrows indicate all FOXP3+ cells. Arrows set as example for CD3+ T cells, not all positive cells are indicated.
FGR, fetal growth restriction; VUE, villitis of unknown etiology.
decidua, we were able to discover higher numbers of Treg cells
and T cells in the maternal compartment of the placenta in
VUE. We hypothesize that the decidual Treg cells increase in
the decidua in order to home toward the villi. The migration of
maternal Treg cells could therefore be seen as a mechanism of
rescuing the failed maternal-fetal tolerance, which complies with
the role of Treg cells in preventing maternal immune responses
toward the allogeneic fetus and placenta (27, 28). Earlier, it has
been shown that the CD3+ T cells infiltrating the fetal villous
tissue are indeed maternal in origin (44, 77). We propose similar
immunophenotyping and in situ hybridization studies with X
and Y chromosome probes in both the decidual tissue and
placental parenchyma to confirm if this also true for Treg cells.
Like in VUE, we found a relative increase in FOXP3+ Treg
cells in both FGR and SB, compared to healthy pregnancies. The
fact that this not correspond to a reduction in Treg cells that is
found in most pregnancy complications, might be attributed to
the high number of placental lesions within our study cohorts,
since we showed that our results did not remain significant after
excluding VUE and multiple lesions in the analysis. Moreover, it
could be explained by the fact that we studied the decidua at term.
A study in allogeneic mice showed that depletion of Tregs early
in pregnancy caused implantation failure and higher resorption
rates, while depletion later in pregnancy did not cause pregnancy
complications like FGR, hypertension, or proteinuria. It has been
suggested that Treg cells are particularly important in the early
phase of pregnancy, but not necessarily for the remainder of
pregnancy (28), which could explain why we do not find lower
FOXP3+ expression in our term decidual samples of FGR and SB
pregnancies. Notably, numbers of FOXP3+ cells are very low in
our study cohorts (on average 2–3 cells/mm2), likely explained
by the physiological decline in Treg cells as delivery approaches
(32). We suggest studying Treg cells in the first and second
trimester, for example in maternal blood or in placental tissue
after pregnancy terminations, to observe possible alterations in
Treg cells over the course of FGR and SB pregnancies.
Concerning decidual CD56+ NK cells, we did not find
differences between FGR and SB and healthy pregnancies.
Previously, lower levels of uterine NK cells have been found
in FGR (49) and this decline in NK cell levels in FGR
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FIGURE 7 | Comparison of immune cell subsets and ratios between placental lesions within the FGR cohort. (A) Numbers of cells/mm2 are shown for CD68+
macrophages, CD206+ M2 macrophages, CD3+ T cells, FOXP3+ Treg cells, and CD56+ NK cells and compared between placental lesions [MVM (n = 18), FVM (n =
17), CA (n = 27), VUE (n = 45), ML (n = 44), and NL (n = 44)] within the FGR cohort with the Kruskal Wallis test and pairwise Dunn’s non-parametric comparison test
as post-hoc test. Data presented as median + IQR. *p < 0.05, **p < 0.01, ***p < 0.001. (B) Ratios of number of cells/mm2 are shown for CD206+/CD68+
macrophages and FOXP3+/CD3+ T cells and compared between placental lesions within the FGR cohort with the Kruskal Wallis test and pairwise Dunn’s
non-parametric comparison test as post-hoc test. Data presented as median + IQR. *p < 0.05, **p < 0.01. MVM, maternal vascular malperfusion; FVM, fetal vascular
malperfusion; CA, chorioamnionitis; VUE, villitis of unknown etiology; ML, multiple lesions; NL, no lesions.
has been associated with impaired placental growth and
trophoblast invasion (78). Different methodological approaches
and inclusion criteria could explain why we could not confirm
these changes. Because our detection classifier is finetuned
for variations in the intensity of IHC and background stains
between tissue slides to prevent major differences in cell count,
the three levels of color intensity (as shown for macrophages
in Supplementary Figure 1) cannot be used to distinguish
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CD56bright from CD56−dim subsets. However, since these subsets
can, respectively, be attributed cytotoxic and immunoregulatory
characteristics (34), it would be interesting to determine if
decidual NK subset imbalances might be involved in FGR and SB.
Interestingly, we found an exceptionally high number of
women who smoked during pregnancy, 100 out of 250 (40%)
in the FGR cohort, 18 out of 64 (28.1%) in the SB cohort,
and 10 out of 42 (23.8%) in the control cohort. Smoking is
known to be a contributing factor to lower birth weights and to
SB (79), and is known to directly harm placental development
and vascularization (80). Alterations in immune cell balances in
women who smoke during pregnancy (>10 cigarettes per day)
have been observed in first trimester decidua and in peripheral
blood (81). In order to see whether our results on macrophages
and Treg cells in the FGR and SB cohort could be influenced
by women’s smoking behavior, we performed a linear regression
analysis, showing that our results on macrophages and Treg
cells in the FGR cohort and Treg cells in the SB cohort were
independent of smoking status. Additionally, we conducted a
sub-analysis in which we excluded all women who smoked from
the three cohorts. Our main finding, the higher numbers of
macrophages in FGR with a decrease of the anti-inflammatory
subset, again remained significant, indicating a strong association
between FGR and altered macrophage levels.
In the selected cases with available histopathologic data from
the DIGITAT (FGR) cohort, 203 out of 250 children were born
with a birth weight below the third centile (81.2%) compared to
the complete DIGITAT study (21.5%). There is a high probability
of inclusion bias with more severe cases included in this study, a
finding which can be explained by a tendency to only submit the
clinically severest cases for placental histopathologic analysis. On
the other hand, it is known that focusing on SGA (usually cut-
off <p10) in a study cohort of FGR provides an overestimation
of the fetuses that are truly growth restricted in that SGA
group (82). By using the worst cases (<p3) for our analysis
chances are low that the results are diluted by healthy SGA
fetuses. However, we strongly advocate to routinely perform
histopathologic examination of all suspected FGR pregnancies
to gain a better understanding of the pathophysiology and
immunology of this complication.
The hypotheses discussed in this study are strengthened by the
extensive number of placenta samples that were included from
large databases derived from the DIGITAT (FGR), ZOBAS (SB),
and NORMA (healthy pregnancies) studies. We have chosen
to adopt the predefined inclusion criteria from these studies,
except for the GA at birth in order to match pregnancy duration
between our cohorts. This could have compromised the use of a
narrower definition of FGR, SB, and healthy neonates, however,
we feel that this does not outweigh the benefits of analyzing
a large study cohort. By developing a detection classifier for
each immune cell subset, we have been able to count the
number of immune cells per surface area of decidual tissue in
a systematic manner reducing observer variability. As the use
of historic patient cohorts limits the availability of the tissue
samples, a selection of IHC markers had to be made. In order
to investigate a variety of immune cells, we have chosen to
use one IHC marker for each subset. No double staining was
performed for this study. Although these markers were carefully
selected, the use of one IHC marker for each subset does limit
the reliability of immune cell identification. In the DIGITAT,
ZOBAS, and NORMA cohorts, biopsies of the superficial part
of the decidua basalis were taken. For future research, it would
be interesting to investigate placental bed biopsies in order to
determine the localization of immune cells with respect to spiral
arteries. It must furthermore be mentioned that, as applies to
any IHC study, the observed decidual immune cell populations
could be the result of non-specific immune cell infiltration
that reflect a maternal immune response to mechanisms like
infarction, hypoxia, or inflammation. The tissue was cut in
consecutive slides were possible and it can therefore be assumed
that numbers of total macrophages and T cells were rather
equal so that CD206+/CD68+ and FOXP3+/CD3+ ratios could
be determined in our samples. Since only paraffin placental
tissue was available from our cohorts, no functionality tests
could be performed. Even though we consider this to be a
limitation of our study, we believe that this methodology does
not compromise our results, nor the aim of this study. Our
findings bring focus to specific immune cell subsets that are
likely involved in the pathogenesis of FGR, SB, and placental
lesions and clearly show immune cell imbalances in these
pregnancy complications. We urge for more in-depth research
with elaborate immunophenotyping and functionality studies to
better characterize these immune cell subsets.
CONCLUSION
FGR and SB are complex and multifactorial pregnancy
complications of which the immunologic background has
received little attention. Due to our historical databases
consisting of a large number of FGR and SB cases with
systematically classified data on placental histopathologic lesions,
this study is the first to analyze immune cell subsets in these
adverse pregnancy outcomes and placenta lesions on a large
scale. Our study indicates a role for macrophages in the
pathophysiology of FGR, with an additional relative decrease of
an anti-inflammatory macrophage subset in FGR. Additionally,
our findings point toward a relative increase of Treg cells in
VUE, FGR, and SB, possibly explained by a compensatory
response to rescue the failed maternal-fetal tolerance. These
insights highlight the importance of further investigating the
functional activity and subset balances of macrophages and
Treg cells in pregnancies complicated by FGR, SB, and
placental lesions.
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